MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ
1.660
-0.150
-8.29%
Closed 16:00 12/01 EST
OPEN
1.700
PREV CLOSE
1.810
HIGH
1.730
LOW
1.645
VOLUME
24.48K
TURNOVER
0
52 WEEK HIGH
4.450
52 WEEK LOW
1.550
MARKET CAP
6.75M
P/E (TTM)
-0.7297
1D
5D
1M
3M
1Y
5Y
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 3d ago
Alterity Therapeutics Ltd: [Cover]SEC-generated letter
Press release · 6d ago
Alterity Therapeutics Ltd: Correspondence
Press release · 6d ago
COCP and ATHE among Health Care movers
Biodexa pharmaceuticals plc (bdrx) and tharimmune (thar) among health care movers. S&p 500 health care sector down 0.36% to 1519.78. Cocp and athe among the top health care names on the list.
Seeking Alpha · 6d ago
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 6d ago
Weekly Report: what happened at ATHE last week (1120-1124)?
Weekly Report · 6d ago
Alterity Therapeutics Earlier Announced Presentation Of Novel Biomarker Data For Evaluation Of Multiple System Atrophy
Alterity therapeutics announces poster presentation at the 34th international symposium on the autonomic nervous system. N-acetylaspartate (naa) is a novel biomarker of neuronal integrity. Naa correlates with levels of neurofilament light chain in patients with multiple system atrophy.
Benzinga · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Impel pharmaceuticals shares moved upwards by 141.4% to $0.77 during thursday's regular session. Conduit pharmaceuticals (nasdaq:cdt) shares rose 37.69%. Telesis bio shares rose 35.58%. Entrada therapeutics stock decreased by 33.1%.
Benzinga · 11/23 17:30
More
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Webull offers Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ: ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.